Tumor cell extracellular vesicles derived long non-coding RNA X-inactive specific transcript regulates the blood–brain barrier and non-small cell lung cancer brain metastasis via miR-19b-3p/EPN2 DOI Creative Commons
Yiqiang Cao, Wenying Chai, Shiming Liu

et al.

Heliyon, Journal Year: 2024, Volume and Issue: unknown, P. e40152 - e40152

Published: Nov. 1, 2024

Language: Английский

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases DOI Creative Commons
Maximilian Marhold, Marta Vaz Batista, Isabel Blancas

et al.

Future Oncology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 9

Published: Feb. 28, 2025

Breast cancer (BC) is the most common cause of leptomeningeal disease (LMD) and second brain metastases (BMs) among all solid malignancies. Both BMs LMD are associated with high morbidity mortality treatment options limited. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate combining a HER2-targeting topoisomerase I inhibitor, has shown activity in HER2-positive (HER2[+]) HER2-low tumors both preclinical clinical settings. Similarly, T-DXd efficacy HER2[+] BC patients central nervous system (CNS) involvement. However, data on and/or using TUXEDO-4 international, multicenter, single-arm, two-stage optimal Simon's design, phase II trial (NCT06048718) that will recruit total 27 adult (13 first stage, 14 stage depending responses stage) to evaluate metastatic population presenting newly diagnosed or progressing BM without type LMD.

Language: Английский

Citations

0
Mechanistic role of stromal cancer-associated fibroblasts in tumorigenesis and brain metastasis: highlighting drug resistance and targeted therapy DOI
Md Rashedunnabi Akanda,

Umme Lubaba,

Md Khalesur Rahman

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155918 - 155918

Published: March 1, 2025

Language: Английский

Citations

0
Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review DOI Creative Commons
Maria Rosaria Valerio, Calogero Cipolla,

Martina Greco

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17

Published: Jan. 1, 2025

Patients with luminal breast cancer (BC) may develop central nervous system metastases in 20%-40% of cases. Radiation or surgical therapy represents the cornerstone treating metastases. Meanwhile, best practice for metastatic BC involves using cyclin-dependent kinase 4/6 inhibitors combined endocrine therapy. To our knowledge, this is first case to report a dramatic response abemaciclib plus without radiation therapy, particularly patient who presented seizures and sudden coma. She received brain surgery control large bleeding metastasis. Abemaciclib was crushed diluted water administration via nasogastric tube, while an upfront fulvestrant given since aromatase cannot be diluted. Beyond radiological response, clinical improvement notable, complete symptom recovery point where she again working. Our paper supports activity from includes review medical literature. Further investigation warranted setting.

Language: Английский

Citations

0
Biological profile of breast cancer brain metastasis DOI Creative Commons
Li Liu, Yuan He, Heng Du

et al.

Acta Neuropathologica Communications, Journal Year: 2025, Volume and Issue: 13(1)

Published: April 19, 2025

Breast cancer is one of the leading causes death worldwide. The aggressive behaviour breast tumor results from their metastasis. Notably, brain tissue common regions metastasis, thereby reducing overall survival patients. Moreover, metastatic tumors demonstrate poor response or resistance to therapies. In addition, metastasis provides prognosis Therefore, it importance understand mechanisms in Both cell lines and animal models have been developed for evaluation different microenvironment components other factors such as lymphocytes astrocytes can affect cells disrupt blood-brain barrier (BBB) during into brain, developing blood-tumor enhance carcinogenesis. be increased by dysregulation chemokines, STAT3, Wnt, Notch PI3K/Akt. On hand, effective therapeutics introduction nanoparticles. disruption BBB ultrasound increase entrance bioactive compounds tissue. order improve specificity selectivity, nanoparticles delivery crossing over suppress

Language: Английский

Citations

0
Targeting the Enhanced Sensitivity of Radiotherapy in Cancer: Mechanisms, Applications, and Challenges DOI Creative Commons
Yuanyuan Zhao,

Fangqin Tan,

Jiajia Zhao

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(6)

Published: May 15, 2025

ABSTRACT Cancer is a major public health, societal, and economic challenge worldwide. According to Global Statistics 2022 , it estimated that by 2050, there will be 35 million new cancer cases globally. Although patient survival rates have improved through various therapeutic approaches, including surgery, chemotherapy, radiotherapy, treatment efficacy remains limited once tumor metastasis occurs. Among strategies, radiotherapy plays crucial role. Along with surgery cost‐effective single‐modality treatment, accounting for approximately 5% of total care costs. The use radiosensitizing agents such as histone deacetylase inhibitors, 2‐deoxy‐ d ‐glucose, enterolactone, squalene epoxidase can enhance effectiveness. Recent radiosensitization methods involve physical stimuli chemical radiosensitizers. However, improving their efficacy, durability, overcoming radioresistance remain significant challenges. This review first introduces current applications in the molecular mechanisms underlying its anticancer effects, side effects. Second, discusses main types radiosensitizers, latest applications, recent challenges treatment. Finally, emphasizes on clinical trials explores potential biomarkers response cancer. Multifunctional nanoparticles shown greater applicability than single‐functional nanoparticles. Future research focus enhancing drug‐carrying capacity nanomaterials further improve outcomes.

Language: Английский

Citations

0
Tumor-on-chip platforms for breast cancer continuum concept modeling DOI Creative Commons

Anca-Narcisa Neagu,

Danielle Whitham, Pathea Bruno

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2024, Volume and Issue: 12

Published: Oct. 2, 2024

Our previous article entitled "Proteomics and its applications in breast cancer", proposed a Breast Cancer Continuum Concept (BCCC), including Cell as well Proteomic Concept. cancer-on-chip (BCoC), cancer liquid biopsy-on-chip (BCLBoC), metastasis-on-chip (BCMoC) models successfully recapitulate reproduce

Language: Английский

Citations

1
Biochemical Signposts: Navigating the Landscape of Early Cancer Diagnosis and Prognostic Insights DOI Open Access

Et al. Khasim Syed

International Journal on Recent and Innovation Trends in Computing and Communication, Journal Year: 2024, Volume and Issue: 11(9), P. 4607 - 4613

Published: Feb. 9, 2024

This exploration investigates the complicated scene of malignant growth from perspective "Biochemical Signs," expecting to upset early analysis and prognostic experiences. Utilizing an exhaustive methodology, biomarkers have distinguished across bosom, lung, prostate tumors, with values going 0.45 3.10. The coordination cutting-edge imaging procedures, including PET X-ray, brought about indicative precision paces 89% 85%, separately. Prognostic investigations divulged biomarkers' shifting effects on understanding endurance, risk proportions 0.70 1.80 p-values featuring factual importance. genomic, proteomic, metabolomic information created all-encompassing sub-atomic profiles, associated unmistakable clinical results. For example, luminal A subtype showed incorporated score 0.85, related a 75% endurance rate. study approves proposed methodology as well lays out its prevalence in exactness, awareness, pertinence when contrasted existing methodologies. blend different types vigor demonstrative devices give establishment groundbreaking headways research customized patient consideration.

Language: Английский

Citations

0
Therapeutic advantage of combinatorial CAR T cell and chemo-therapies DOI Creative Commons

Meghan B Ward,

Amber B. Jones, Giedre Krenciute

et al.

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 77(1), P. 100011 - 100011

Published: Oct. 7, 2024

Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many patients with hematological malignancies. However, some do not respond to CAR treatment, and adapting cells solid brain tumors has been met challenges including a hostile tumor microenvironment poor persistence. Thus, it is unlikely that therapy alone will be sufficient consistent, complete clearance across cancer patients. Combinatorial of chemotherapeutics are promising approach overcoming this as could augment improved anti-tumor activity or work in tandem clear tumors. Herein, we review efforts towards achieving successful chemical drug combination therapies. We focus on approved these more easily translated the clinic, but also non-approved screens designed reveal new combinations. Together, highlights promise chemotherapy combinations specific how combinatorial overcomes faced by either monotherapy supports potential therapeutic strategy improve Significance Statement Improving currently available products via drastically expand types cancers number benefit from when neither achieve clearance. provide thorough current studying perspectives optimal ways identify effective moving forward.

Language: Английский

Citations

0
Tumor cell extracellular vesicles derived long non-coding RNA X-inactive specific transcript regulates the blood–brain barrier and non-small cell lung cancer brain metastasis via miR-19b-3p/EPN2 DOI Creative Commons
Yiqiang Cao, Wenying Chai, Shiming Liu

et al.

Heliyon, Journal Year: 2024, Volume and Issue: unknown, P. e40152 - e40152

Published: Nov. 1, 2024

Language: Английский

Citations

0